Literature DB >> 18635757

Practical therapeutic drug management in HIV-infected patients: use of population pharmacokinetic models supplemented by individualized Bayesian dose optimization.

Michael Neely1, Roger Jelliffe.   

Abstract

Individualized, model-based, target-oriented optimal concentration-controlled dosing of HIV medications can be beneficial to patients for whom there are limited dosing guidelines, such as children, adolescents, or patients with altered physiologic function. Barriers to this approach include lack of training, expertise, and access to appropriate software to assist the clinician. The authors present 4 illustrative clinical cases of HIV-infected patients whose therapy was optimized using population pharmacokinetic models (here generated from published studies) and supplemented by individualized Bayesian adaptive control of dosage regimens as implemented in the MM-USCPACK software. These 4 cases illustrate how clinicians can maximize therapeutic success in (1) patients with reduced drug clearance, (2) young adolescents transitioning to adult physiology, (3) patients with dose-dependent toxicity, and (4) adolescents with limited therapeutic options.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18635757      PMCID: PMC2724306          DOI: 10.1177/0091270008321789

Source DB:  PubMed          Journal:  J Clin Pharmacol        ISSN: 0091-2700            Impact factor:   3.126


  48 in total

1.  Pharmacologic optimization of protease inhibitors and nonnucleoside reverse transcriptase inhibitors (POPIN)--a randomized controlled trial of therapeutic drug monitoring and adherence support.

Authors:  Saye H Khoo; Judith Lloyd; Mark Dalton; Alec Bonington; Elizabeth Hart; Sara Gibbons; Peter Flegg; John Sweeney; Edmund G L Wilkins; David J Back
Journal:  J Acquir Immune Defic Syndr       Date:  2006-04-01       Impact factor: 3.731

2.  Can responses to antiretroviral therapy be improved by therapeutic drug monitoring?

Authors:  David W Haas
Journal:  Clin Infect Dis       Date:  2006-03-07       Impact factor: 9.079

3.  Parametric and nonparametric population methods: their comparative performance in analysing a clinical dataset and two Monte Carlo simulation studies.

Authors:  Aida Bustad; Dimiter Terziivanov; Robert Leary; Ruediger Port; Alan Schumitzky; Roger Jelliffe
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

4.  Interpatient variability in the pharmacokinetics of the HIV non-nucleoside reverse transcriptase inhibitor efavirenz: the effect of gender, race, and CYP2B6 polymorphism.

Authors:  David Burger; Ilse van der Heiden; Charles la Porte; Marchina van der Ende; Paul Groeneveld; Clemens Richter; Peter Koopmans; Frank Kroon; Herman Sprenger; Jan Lindemans; Paul Schenk; Ron van Schaik
Journal:  Br J Clin Pharmacol       Date:  2006-02       Impact factor: 4.335

Review 5.  Developmental pharmacology: ontogenic basis of drug disposition.

Authors:  M D Reed; J B Besunder
Journal:  Pediatr Clin North Am       Date:  1989-10       Impact factor: 3.278

6.  Marked intraindividual variability in antiretroviral concentrations may limit the utility of therapeutic drug monitoring.

Authors:  Richard E Nettles; Tara L Kieffer; Teresa Parsons; James Johnson; Joseph Cofrancesco; Joel E Gallant; Kathryn A Carson; Robert F Siliciano; Charles Flexner
Journal:  Clin Infect Dis       Date:  2006-03-07       Impact factor: 9.079

7.  A randomized controlled trial to evaluate antiretroviral salvage therapy guided by rules-based or phenotype-driven HIV-1 genotypic drug-resistance interpretation with or without concentration-controlled intervention: the Resistance and Dosage Adapted Regimens (RADAR) study.

Authors:  Carlo Torti; Eugenia Quiros-Roldan; Mario Regazzi; Andrea De Luca; Francesco Mazzotta; Andrea Antinori; Nicoletta Ladisa; Valeria Micheli; Anna Orani; Andrea Patroni; Paola Villani; Sergio Lo Caputo; Francesca Moretti; Simona Di Giambenedetto; Filippo Castelnuovo; Paolo Maggi; Carmine Tinelli; Giampiero Carosi
Journal:  Clin Infect Dis       Date:  2005-05-12       Impact factor: 9.079

8.  The use of pharmacokinetically guided indinavir dose reductions in the management of indinavir-associated renal toxicity.

Authors:  Mark A Boyd; Umaporn Siangphoe; Kiat Ruxrungtham; Peter Reiss; Apicha Mahanontharit; Joep M A Lange; Praphan Phanuphak; David A Cooper; David M Burger
Journal:  J Antimicrob Chemother       Date:  2006-04-04       Impact factor: 5.790

Review 9.  Fosamprenavir : clinical pharmacokinetics and drug interactions of the amprenavir prodrug.

Authors:  Mary Beth Wire; Mark J Shelton; Scott Studenberg
Journal:  Clin Pharmacokinet       Date:  2006       Impact factor: 6.447

10.  Age-related effects on nelfinavir and M8 pharmacokinetics: a population study with 182 children.

Authors:  Déborah Hirt; Saïk Urien; Vincent Jullien; Ghislaine Firtion; Elisabeth Rey; Gérard Pons; Stéphane Blanche; Jean-Marc Treluyer
Journal:  Antimicrob Agents Chemother       Date:  2006-03       Impact factor: 5.191

View more
  18 in total

1.  Accurate detection of outliers and subpopulations with Pmetrics, a nonparametric and parametric pharmacometric modeling and simulation package for R.

Authors:  Michael N Neely; Michael G van Guilder; Walter M Yamada; Alan Schumitzky; Roger W Jelliffe
Journal:  Ther Drug Monit       Date:  2012-08       Impact factor: 3.681

2.  Are vancomycin trough concentrations adequate for optimal dosing?

Authors:  Michael N Neely; Gilmer Youn; Brenda Jones; Roger W Jelliffe; George L Drusano; Keith A Rodvold; Thomas P Lodise
Journal:  Antimicrob Agents Chemother       Date:  2013-10-28       Impact factor: 5.191

Review 3.  Pharmacokinetic optimization of antiretroviral therapy in children and adolescents.

Authors:  Michael N Neely; Natella Y Rakhmanina
Journal:  Clin Pharmacokinet       Date:  2011-03       Impact factor: 6.447

Review 4.  Optimising antimicrobial therapy through the use of Bayesian dosing programs.

Authors:  M L Avent; B A Rogers
Journal:  Int J Clin Pharm       Date:  2019-08-07

Review 5.  Benchmarking therapeutic drug monitoring software: a review of available computer tools.

Authors:  Aline Fuchs; Chantal Csajka; Yann Thoma; Thierry Buclin; Nicolas Widmer
Journal:  Clin Pharmacokinet       Date:  2013-01       Impact factor: 6.447

6.  Can therapeutic drug monitoring improve pharmacotherapy of HIV infection in adolescents?

Authors:  Natella Y Rakhmanina; John N van den Anker; Steven J Soldin; Ron H van Schaik; Nick Mordwinkin; Michael N Neely
Journal:  Ther Drug Monit       Date:  2010-06       Impact factor: 3.681

7.  Population pharmacokinetics and maximum a posteriori probability Bayesian estimator of abacavir: application of individualized therapy in HIV-infected infants and toddlers.

Authors:  Wei Zhao; Massimo Cella; Oscar Della Pasqua; David Burger; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2012-04       Impact factor: 4.335

8.  A Nonparametric Method to Optimize Initial Drug Dosing and Attainment of a Target Exposure Interval: Concepts and Application to Busulfan in Pediatrics.

Authors:  Michaël Philippe; Michael Neely; Yves Bertrand; Nathalie Bleyzac; Sylvain Goutelle
Journal:  Clin Pharmacokinet       Date:  2017-04       Impact factor: 6.447

Review 9.  Pharmacokinetic modeling of therapies for systemic lupus erythematosus.

Authors:  Xiaoyan Yang; Catherine M T Sherwin; Tian Yu; Venkata K Yellepeddi; Hermine I Brunner; Alexander A Vinks
Journal:  Expert Rev Clin Pharmacol       Date:  2015-07-09       Impact factor: 5.045

Review 10.  Paediatric models in motion: requirements for model-based decision support at the bedside.

Authors:  Jeffrey S Barrett
Journal:  Br J Clin Pharmacol       Date:  2015-01       Impact factor: 4.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.